Search

Background: Efficacy and safety profile of COVID-19 vaccines had been acquired from phase III studies. Nevertheless, cancer patients were not represented in these trials. In 1/2021 mass vaccination of high-risk population, including cancer patients, was initiated in Israel. We aimed to prospectively evaluate efficacy, immunogenicity and safety of BNT162b2 vaccine in cancer patients. Methods: Cancer patients on active treatment were prospectively enrolled following first dose of BNT162b2 or after a second dose. Serum was collected after each dose and additionally in case of seronegativity. An age-matched cohort of healthcare workers served as controls. Questionnaires regarding sociodemographics and adverse reactions were employed at serum collection. FDA-approved assay was used to assess IgG at all time-points. Patients’ electronic medical records were reviewed for documentation of COVID-19 infection, blood counts, liver enzymes and imaging studies. Results: The study included 232 cancer patients and 261 controls. Following first dose 29% of patients were seropositive compared with 84% of controls (p

Background: Young cancer patients (YCP) face unique obstacles and unmet needs as treatment-induced endocrine disorders, late-term complications and psychosocial perspectives. Currently there are no formal programs to comprehensively address these unmet needs but rather scarce disease-oriented services. We hypothesize that proactive intervention of broadly-designated support for YCP will optimize their coping with the disease and side effects, improve quality of life (QOL) and yield better fertility preservation rate. We aimed to assess the implementation of an “oncoyoung program” using a predefined protocol of patient triage to fertility preservation (FP), supportive care and psychosocial support on patients’ satisfaction rate. Methods: “Oncoyoung” program (for patients